Affiliation:
1. Department of Neurology, Narayana Hrudayalaya, Bengaluru, Karnataka, India
Abstract
Abstract
Aripiprazole, a novel neuroleptic and dopamine system stabilizer, is hailed as 3rd generation neuroleptic by some and claimed to have partial agonistic activity at D2 receptors (D2R), distinguishing it from other antipsychotics-D2 dopamine receptor antagonists. Many studies have extensively described extrapyramidal syndrome (EPS) profiles of earlier atypical neuroleptics including clozapine, quetiapine, olanzapine, ziprasidone, and risperidone. Despite the claimed D2R agonistic mechanism, EPS due to aripiprazole is sporadically reported – here below we report two such cases across two different baselines. One in a patient with no baseline Parkinsonism, another in a patient with well controlled Parkinson’s disease.
Reference8 articles.
1. The dopamine hypothesis of schizophrenia: A review;Meltzer;Schizophr Bull,1976
2. Half a century of antipsychotics and still a central role for dopamine D2 receptors;Kapur;Prog Neuropsychopharmacol Biol Psychiatry,2003
3. Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors;Millan;J Pharmacol Exp Ther,2000
4. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor;Jordan;Eur J Pharmacol,2002
5. Aripiprazole: A dopamine-serotonin system stabilizer;McQuade;Int J Neuropsychopharmacol,2002